Titlebook: Cardiac Allograft Rejection; G William Dec,Jagat Narula (Director),Ignasi Carri Book 2001 Springer Science+Business Media New York 2001 Im

抗體

死亡率

New Immunosuppressive Agentscuses on those small molecules that have shown to have immunosuppressive activity in patients. (Fig.1). Two monoclonal antibodies are also included as examples of a resurgence of development in this area.

Adulterate

lved from an unproven experimental surgicaltechnique to the most effective form of therapy for refractoryend-stage heart disease. It has captured the public‘s imagination andexpanded our understanding of fundamental immunologic mechanisms thatare responsible for cellular and humorally-mediated immun

Conquest

P. Veltri,F. Malara,L. Primaveraovations in managing acute rejection and infection, particularly cytomegalovirus (CMV) infection. Despite the substantial improvement in early survival, the long-term survival rate has not increased during the past decade.

暫時(shí)中止

Popcorn

Holm Altenbach,Marco Amabili,Yuri V. Mikhlinnd 1.3 at 3, 6, and 12 months post-transplant, repectively (Figure 1A).. Actuarial freedom from first treated rejection episode was 39% at 6 months and 37% at 12 months (Figure IB). Overall, more than 90% of all rejection episodes occur in the first six months post-transplant..

巨頭

Nonlinear Mechanics of Complex Structuresensive, time-consuming and not 100% sensitive since sampling error may occur. These limitations have createda need for developing an inexpensive, non-invasive methods to assess the entireallograft for rejection and to follow its response to therapy

Heart-Rate

byline

結(jié)果

Endomyocardial Biopsy Diagnosis of Cardiac Allograft Rejectionptomes made endomyocardial biopsy safer and more widely used, becoming a valuable tool in the diagnosis of cardiac diseases.. It also introduced a working link between the pathologist and clinical cardiologist..